Novartis successfully completes acquisition of Endocyte

Transforming patients’ lives by leading innovation in nuclear medicine

nuclear medicine R&D

Our Work

Our work is guided by our commitment to bring new innovations to patients.

AAA is developing a pipeline of nuclear medicine theragnostic pairings for oncology indications. Our theragnostic platform involves radiolabeling a targeting molecule with fluorine 18 (F-18), gallium 68 (Ga-68), or other radionuclides used for precision radioligand imaging, or with lutetium 177 (Lu-177), actinium 225 (Ac-225) or other radionuclides used for treatment to create a targeted radioligand therapy.

Our other products include radiopharmaceuticals for molecular imaging with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Look For Clinical Trials?

Find a clinical trial in your area

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to diagnose and treat disease.

nuclear medicine clinical trials

Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Dec 3, 2018

Advanced Accelerator Applications signs exclusive option and license agreement w…

Oct 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonst…

Jun 22, 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical…

by @adacap_news
#NuclearMedicine imaging often enables physicians to accurately diagnose and stage complex diseases including…